Cure8 research brief
If sex influences response to 5-ASA, that could affect treatment expectations and shared decision-making. The letter warns that the original study’s results may not apply to people who smoke, so smokers and their clinicians may need more specific evidence.
Clinicians; researchers studying treatment modifiers in UC; patients with ulcerative colitis—particularly smokers or those interested in medication response differences by sex.
The letter does not present new trial data but critiques methods and generalizability of a published study, emphasizing that smokers may not have been adequately represented or analyzed. It calls for external validation of the original findings in smokers and clearer reporting on disease duration.
This is a letter critiquing another study’s methodology and generalizability; it does not report new patient-level outcomes. The recommendation is for further analyses or validation rather than a change in care based on this letter alone.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.
Many people with Crohn’s disease or ulcerative colitis use biologic drugs; new clinical and real-world data about a subcutaneous infliximab option could affect treatment choice, switching decisions, and practical use in...
A newly approved biologic, Omvoh (mirikizumab), gives another FDA‑approved treatment option for adults with moderate to severe Crohn’s disease and adds to Lilly’s role in IBD care.
